Compound useful for the treatment of degenerative and inflammatory diseases
US-9707237-B2 · Jul 18, 2017 · US
Compound useful for the treatment of degenerative and inflammatory diseases
US10328081B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10328081-B2 |
| Application number | US-201715651116-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 17, 2017 |
| Priority date | Jun 26, 2009 |
| Publication date | Jun 25, 2019 |
| Grant date | Jun 25, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of psoriatic arthritis, comprising: administering to a subject in need thereof an amount of a compound according to Formula I: or a pharmaceutically acceptable salt thereof sufficient to effect said treatment. 2. The method according to claim 1 , wherein the compound is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriatic arthritis. 3. The method according to claim 2 , wherein the compound is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriatic arthritis. 4. A method for the treatment of psoriatic arthritis, comprising: administering to a subject in need thereof an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I: or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment. 5. A method for the treatment of psoriatic arthritis, comprising: administering to a subject in need thereof an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a pharmaceutically effective amount of a compound according to Formula I: or a pharmaceutically acceptable salt thereof, and a further therapeutic agent, sufficient to effect said treatment. 6. The method according to claim 4 , wherein the pharmaceutical composition is administered in combination with one or more further therapeutic agents selected from agents for the treatment of psoriatic arthritis. 7. The method according to claim 6 , wherein the pharmaceutical composition is administered in combination with one further therapeutic agent selected from agents for the treatment of psoriatic arthritis. 8. The method according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of psoriatic arthritis.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10328081B2 cover?
- A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, aut…
- Who is the assignee on this patent?
- Galapagos Nv
- What technology area does this patent fall under?
- Primary CPC classification A61K31/541. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).